Clinical analysis of the serum CA125, LDH level in patients with non-Hodgkin lymphoma / 白血病·淋巴瘤

Objective To investigate the level of serum cancer antigen 125 (CA125) and lactic dehydrogenase(LDH) and clinical features of patients with non-Hodgkin lymphoma(NHL), and the correlation between the level of serum CA125 and LDH. Methods Forty patients with NHL were studied and the variances of the serum CA125, LDH level before treatment were analysed. Results A higher serum of CA125was associated with clinical phase,group,hydrothorax and ascites,intemational prognostic index (IPI), and had weaker positive correlation to LDH. Conclusion Measurement of serum CA125 had important clinical significance to the patients with NHL especially to the patients with hydrothorax and ascites.

A prospective randomized trial comparing mitomycin C and vindesine and cisplatin versus pirarubicin and vindesine and cisplatin in the treatment of advanced non-small cell lung cancer / 中国肺癌杂志

<p><b>BACKGROUND</b>To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen.</p><p><b>METHODS</b>Sixty six patients with advanced non-small cell lung cancer were randomized into two groups:MVP arm (32 patients, mitomycin C 6-8 mg/m² d1, vindesine 2-3 mg/m² d1 and d8, cisplatin 70-80 mg/m² d1) and TVP arm (34 patients, pirarubicin 40-50 mg/m² d1, vindesine and cisplatin were the same as arm MVP). Characteristics of the patients were similar in two arms. All patients received two to four cycles of chemotherapy.</p><p><b>RESULTS</b>The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological toxicities. Grade III+IV hematological toxicities were significantly higher in the patients of arm TVP than arm MVP, especially neutropenia (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively..</p><p><b>CONCLUSIONS</b>MVP regimen has a lower response rate and longer survival time but less hematological toxicities than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced non-small cell lung cancer.</p>